公开(公告)号：US10233152B2

公开(公告)日：2019-03-19

申请号：US15725949

申请日：2017-10-05

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  Arkadii Vaisburg ,  James Gail Christensen ,  Robert Anthony Galemmo, Jr.

IPC: C07D211/58 ,  C07D205/04 ,  C07D211/76 ,  C07D211/88 ,  C07D221/22 ,  C07D401/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D265/10 ,  C07D213/64

Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US20190062330A1

公开(公告)日：2019-02-28

申请号：US16173726

申请日：2018-10-29

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： James F. Blake ,  Laurence E. Burgess ,  Mark Joseph Chicarelli ,  James Gail Christensen ,  Jay Bradford Fell ,  John P. Fischer ,  John J. Gaudino ,  Erik James Hicken ,  Ronald Jay Hinklin ,  Matthew Randolf Lee ,  Matthew Arnold Marx ,  Macedonio J. Mejia ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P.A. Vigers ,  Henry J. Zecca

IPC: C07D471/04 ,  C07D519/00

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.